These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34250760)

  • 1. Diagnostic and prognostic value of stem cell factor plasma level in glioblastoma multiforme patients.
    Kefayat A; Amouheidari A; Ghahremani F; Alirezaei Z
    Cancer Med; 2021 Aug; 10(15):5154-5162. PubMed ID: 34250760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.
    Gállego Pérez-Larraya J; Paris S; Idbaih A; Dehais C; Laigle-Donadey F; Navarro S; Capelle L; Mokhtari K; Marie Y; Sanson M; Hoang-Xuan K; Delattre JY; Mallet A
    Cancer; 2014 Dec; 120(24):3972-80. PubMed ID: 25139333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
    Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
    Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
    Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
    PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and Prognostic Value of Circulating DNA Fragments in Glioblastoma Multiforme Patients.
    Jarmuzek P; Wawrzyniak-Gramacka E; Morawin B; Tylutka A; Zembron-Lacny A
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Survival in Turkish Patients with Primary Glioblastoma.
    Bilgin E; Duman BB; Altintas S; Cil T; Gezercan Y; Okten AI
    Turk Neurosurg; 2021; 31(4):641-653. PubMed ID: 33759174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.
    Romano A; Calabria LF; Tavanti F; Minniti G; Rossi-Espagnet MC; Coppola V; Pugliese S; Guida D; Francione G; Colonnese C; Fantozzi LM; Bozzao A
    Eur Radiol; 2013 Feb; 23(2):513-20. PubMed ID: 22875158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients.
    Zhang H; Wang J; Wang Z; Ruan C; Wang L; Guo H
    Cancer Biomark; 2019; 24(1):43-49. PubMed ID: 30530966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
    Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
    Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
    Iliadis G; Kotoula V; Chatzisotiriou A; Televantou D; Eleftheraki AG; Lambaki S; Misailidou D; Selviaridis P; Fountzilas G
    BMC Cancer; 2012 Jan; 12():3. PubMed ID: 22214427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme.
    Bennett IE; Guo H; Kountouri N; D'abaco GM; Hovens CM; Moffat BA; Desmond P; Drummond K; Kaye AH; Morokoff AP
    J Clin Neurosci; 2015 Nov; 22(11):1802-8. PubMed ID: 26308396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
    Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
    J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
    Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme.
    Greenfield JP; Jin DK; Young LM; Christos PJ; Abrey L; Rafii S; Gutin PH
    Neurosurgery; 2009 May; 64(5):819-26; discussion 826-7. PubMed ID: 19404145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study.
    Bagley SJ; Nabavizadeh SA; Mays JJ; Till JE; Ware JB; Levy S; Sarchiapone W; Hussain J; Prior T; Guiry S; Christensen T; Yee SS; Nasrallah MP; Morrissette JJD; Binder ZA; O'Rourke DM; Cucchiara AJ; Brem S; Desai AS; Carpenter EL
    Clin Cancer Res; 2020 Jan; 26(2):397-407. PubMed ID: 31666247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of serum levels and tissue expression of two genes IGFBP-2 and IGFBP-3 act as potential biomarker for predicting the progression and survival in patients with glioblastoma multiforme.
    Abdolhoseinpour H; Mehrabi F; Shahraki K; Khoshnood RJ; Masoumi B; Yahaghi E; Goudarzi PK
    J Neurol Sci; 2016 Jul; 366():202-206. PubMed ID: 27288807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.
    Laxton RC; Popov S; Doey L; Jury A; Bhangoo R; Gullan R; Chandler C; Brazil L; Sadler G; Beaney R; Sibtain N; King A; Bodi I; Jones C; Ashkan K; Al-Sarraj S
    Neuro Oncol; 2013 Dec; 15(12):1635-43. PubMed ID: 24158110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
    Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
    Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme.
    Tan SK; Pastori C; Penas C; Komotar RJ; Ivan ME; Wahlestedt C; Ayad NG
    Mol Cancer; 2018 Mar; 17(1):74. PubMed ID: 29558959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.